Category: News & Comments
Biocryst: A Major Game Changing Agreement
On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website about an important agreement Biocryst Pharmaceuticals (BCRX) signed with CSL We expect the agreement to contribute a great deal into bringing effective treatments of...
Read More
June 22, 2015
0
Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles
Today it is Greece. What About Tomorrow? Can Greece's crisis devastate the biotech sector? No sane individual would think so and the hysteria cannot be called other than what it is. The biotech sector is not overvalued and its value...
Read More
June 29, 2015
0
TrovaGene: Overcoming Challenges in Cancer Immunotherapy
After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer immunotherapy), novel approaches based on new discoveries have finally demonstrated they can do the hard job. These treatments, however, are facing challenges which must...
Read More
July 8, 2015
0
Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why Is This Great News?
An Effective Non-Steroid Atopic Dermatitis Ointment Anacor Pharmaceuticals (ANAC) Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis Crisaborole is a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor...
Read More
July 14, 2015
0
Amgen: Repatha Approved in Europe
The European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab). The First PCSK9 Inhibitor to Be Approved in the World for Treatment of High Cholesterol. A Critical Milestone for Patients with Uncontrolled Cholesterol Who Require Additional Intensive LDL-C Reduction. Amgen...
Read More
July 21, 2015
0
Exelixis: The Importance of the Public Offering. Xoma: What Should We Do Now?
Why the financing through a secondary public offering was a must for Exelixis. The outcome of the public offering is putting in Exelixis’ (EXEL) coffers around $128 million, which we know the firm will definitely need for the development of...
Read More
July 23, 2015
0
NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?
The moment the new IPO NantKwest ( NK ) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed...
Read More
August 3, 2015
0
Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination
In The NEWS IMMUNOTHERAPY MIRATI THERAPEUTICS Mirati Therapeutics (MRTX) is an oncology company focusing on genetic and epigenetic drivers of cancer. The firm’s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development...
Read More
August 6, 2015
0
Inovio Is in Much Better Shape Than Six Months Ago
INOVIO Inovio Pharmaceuticals (INO) is much worth looking at now than 6 months ago. The deal signed between MedImmune, AstraZeneca’s development arm, and Inovio Pharmaceuticals says something. The DEAL MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy against cancers caused...
Read More
August 13, 2015
0
Kite: News We Are Anxious to Hear
Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms that are designing and developing CAR T Cell immunotherapy treatments for cancer. Many investors are wondering about the plummeting of the stock and obviously...
Read More
August 17, 2015
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)